Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Saved in:
| Title: | Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. |
|---|---|
| Authors: | Duong VH; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Ruppert AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Mims AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Borate U; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Baer MR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Stock W; Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA., Kovacsovics T; Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah, USA., Blum W; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Arellano ML; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Schiller GJ; David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California, USA., Olin RL; Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California, USA., Foran JM; Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA., Litzow MR; Departments of Medical Oncology, Hematology, and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA., Lin TL; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Patel PA; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA., Foster MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA., Redner RL; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Al-Mansour Z; Department of Medicine, University of Florida, Gainesville, Florida, USA., Cogle CR; Department of Medicine, University of Florida, Gainesville, Florida, USA., Swords RT; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Collins RH; University of Texas Southwestern Medical Center Medical School, Dallas, Texas, USA., Vergilio JA; Foundation Medicine, Cambridge, Massachusetts, USA., Heerema NA; Department of Pathology, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Rosenberg L; The Leukemia & Lymphoma Society, Rye Brook, New York, USA., Yocum AO; The Leukemia & Lymphoma Society, Rye Brook, New York, USA., Marcus S; The Leukemia & Lymphoma Society, Rye Brook, New York, USA., Chen T; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Druggan F; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Stefanos M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Gana TJ; Biopharmatech Consulting, Inc., Leesburg, Virginia, USA., Shoben AB; Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, USA., Druker BJ; Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Burd A; The Leukemia & Lymphoma Society, Rye Brook, New York, USA., Byrd JC; Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA., Levine RL; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Boyiadzis MM; Hillman Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. |
| Source: | Cancer [Cancer] 2023 Aug 01; Vol. 129 (15), pp. 2308-2320. Date of Electronic Publication: 2023 Apr 20. |
| Publication Type: | Multicenter Study; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.34780 |
